Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma

This proof-of-concept single-arm open-label phase I clinical trial (NCT02481934) studied the safety and efficacy of multiple infusions of activated and expanded natural killer (NKAE) cells in combination with anti-myeloma drugs in multiple myeloma patients. It included five patients with relapsed or...

Descripción completa

Detalles Bibliográficos
Autores principales: Leivas, Alejandra, Perez-Martinez, Antonio, Blanchard, María Jesús, Martín-Clavero, Estela, Fernández, Lucía, Lahuerta, Juan José, Martinez-Lopez, Joaquín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5213771/
https://www.ncbi.nlm.nih.gov/pubmed/28123890
http://dx.doi.org/10.1080/2162402X.2016.1250051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5213771/
https://www.ncbi.nlm.nih.gov/pubmed/28123890
http://dx.doi.org/10.1080/2162402X.2016.1250051

Ejemplares similares